Table 5.
Cancer mortality and incidence risks at selected cancer sites, SAGhE cohort, by duration since first treatment and initial diagnosis leading to GH treatment
| All initial diagnoses, total | |||||
|---|---|---|---|---|---|
| Cancer mortality |
Cancer incidenceb |
||||
| Cancer site (outcome) | Duration since first treatment (years) | n | SMRa (95% CI) | n | SIR (95% CI) |
| Colorectal cancer | 0-9 | 1 | 10.2 (0.3-56.7) | 2 | 4.2 (1.1-16.9)c |
| 10-19 | 1 | 2.7 (0.1-15.1) | 2 | 2.0 (0.5-7.9) | |
| 20-29 | 0 | 0.0 (0.0-45.2) | 0 | 0.0 (0.0-16.4) | |
| p trend | 0.25 | 0.25 | |||
| Bone cancer | 0-9 | 9 | 8.5 (4.4-16.3)e | 5 | 4.6 (1.9-11.0)c |
| 10-19 | 3 | 4.6 (1.5-14.2)c | 4 | 6.8 (2.6-18.1)d | |
| 20-29 | 0 | 0.0 (0.0-114.7) | 0 | 0.0 (0.0-86.2) | |
| p trend | 0.30 | 0.76 | |||
| Melanoma | 0-9 | 0 | 0.0 (0.0-25.2) | 2 | 1.6 (0.4, 6.2) |
| 10-19 | 1 | 2.1 (0.1-11.9) | 7 | 1.9 (0.9, 4.0) | |
| 20-29 | 0 | 0.0 (0.0-45.4) | 3 | 4.5 (1.4, 13.8)c | |
| p trend | 0.86 | 0.25 | |||
| CNS | 0-9 | 120 | 62.9 (52.6-75.2)e | 15 | 6.2 (3.8-10.3)e |
| 10-19 | 32 | 24.2 (17.1-34.3)e | 13 | 7.2 (4.2-12.4)e | |
| 20-29 | 4 | 22.9 (8.6-61.0)e | 1 | 4.7 (0.1-26.2) | |
| p trend | <0.001 | 0.90 | |||
| Thyroid | 0-9 | 0 | 0.0 (0.0-1284.3) | 6 | 10.9 (4.9-24.2)e |
| 10-19 | 1 | 78.1 (2.0-435.4)c | 5 | 4.1 (1.7-9.8)c | |
| 20-29 | 0 | 0.0 (0.0-1393.9) | 1 | 4.4 (0.1-24.6) | |
| p trend | 0.98 | 0.14 | |||
| Hodgkin lymphoma | 0-9 | 0 | 0.0 (0.0-17.0) | 0 | 0.0 (0.0-1.8) |
| 10-19 | 0 | 0.0 (0.0-11.3) | 6 | 2.7 (1.2-6.0)c | |
| 20-29 | 0 | 0.0 (0.0-119.2) | 2 | 9.6 (2.4-38.2)c | |
| p trend | - | 0.001 | |||
| Leukaemia | 0-9 | 20 | 7.7 (5.0-11.9)e | 4 | 2.0 (0.8-5.4) |
| 10-19 | 7 | 4.7 (2.3-9.9)d | 3 | 2.7 (0.9-8.4) | |
| 20-29 | 0 | 0.0 (0.0-32.6) | 0 | 0.0 (0.0-30.5) | |
| p trend | 0.16 | 0.98 | |||
| Initial diagnosis cancer |
Initial diagnosis non-cancer |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer mortality |
Cancer incidenceb |
Cancer mortality |
Cancer incidenceb |
||||||
| Cancer site (outcome) | Duration since first treatment (years) | n | SMRa (95% CI) | n | SIR (95% CI) | n | SMRa (95% CI) | n | SIR (95% CI) |
| Colorectal cancer | 0-9 | 1 | 74.4 (1.9-414.4)c | 2 | 24.4 (6.1-97.6)d | 0 | 0.0 (0.0-43.5) | 0 | 0.0 (0.0-9.4) |
| 10-19 | 0 | 0.0 (0.0-85.4) | 0 | 0.0 (0.0-24.7) | 1 | 3.1 (0.1-17.1) | 2 | 2.3 (0.6-9.3) | |
| 20-29 | 0 | 0.0 (0.0-319.9) | 0 | 0.0 (0.0-96.7) | 0 | 0.0 (0.0-52.6) | 0 | 0.0 (0.0-19.7) | |
| p trend | 0.11 | 0.06 | 0.97 | 0.75 | |||||
| Bone cancer | 0-9 | 7 | 47.8 (22.8-100.3)e | 3 | 14.8 (4.8-45.9)d | 2 | 2.2 (0.5-8.7) | 2 | 2.3 (0.6-9.0) |
| 10-19 | 1 | 13.3 (0.3-74.2) | 2 | 24.7 (6.2-98.8)d | 2 | 3.5 (0.9-13.8) | 2 | 3.9 (1.0-15.8) | |
| 20-29 | 0 | 0.0 (0.0-915.9) | 0 | 0.0 (0.0-561.5) | 0 | 0.0 (0.0-131.2) | 0 | 0.0 (0.0-101.8) | |
| p trend | 0.19 | 0.82 | 0.76 | 0.74 | |||||
| Melanoma | 0-9 | 0 | 0.0 (0.0-178.8) | 1 | 4.3 (0.1-23.9) | 0 | 0.0 (0.0-29.4) | 1 | 0.9 (0.0-5.3) |
| 10-19 | 0 | 0.0 (0.0-65.6) | 2 | 3.8 (0.9-15.1) | 1 | 2.4 (0.1-13.6) | 5 | 1.6 (0.7-3.9) | |
| 20-29 | 0 | 0.0 (0.0-299.2) | 2 | 18.9 (4.7-75.6)c | 0 | 0.0 (0.0-53.5) | 1 | 1.8 (0.0-9.8) | |
| p trend | - | 0.22 | 0.86 | 0.64 | |||||
| CNS | 0-9 | 118 | 503.2 (420.1-602.7)e | 11 | 29.3 (16.2-52.9)e | 2 | 1.2 (0.3-4.8) | 4 | 2.0 (0.7-5.2) |
| 10-19 | 31 | 207.3 (145.8-294.8)e | 11 | 43.4 (24.0-78.3)e | 1 | 0.9 (0.0-4.8) | 2 | 1.3 (0.3-5.1) | |
| 20-29 | 4 | 155.1 (58.2-413.3)e | 1 | 29.8 (0.8-165.9) | 0 | 0.0 (0.0-24.8) | 0 | 0.0 (0.0-20.6) | |
| p trend | <0.001 | 0.43 | 0.64 | 0.47 | |||||
| Thyroid | 0-9 | 0 | 0.0 (0.0-10035.5) | 5 | 51.3 (21.4-123.3)e | 0 | 0.0 (0.0-1472.7) | 1 | 2.2 (0.1-12.3) |
| 10-19 | 1 | 772.6 (19.6-4304.7)d | 4 | 22.5 (8.4-59.9)e | 0 | 0.0 (0.0-320.7) | 1 | 1.0 (0.0-5.3) | |
| 20-29 | 0 | 0.0 (0.0-10488.7) | 1 | 28.4 (0.7-158.1) | 0 | 0.0 (0.0-1607.5) | 0 | 0.0 (0.0-19.3) | |
| p trend | 0.99 | 0.29 | - | 0.41 | |||||
| Hodgkin lymphoma | 0-9 | 0 | 0.0 (0.0-123.2) | 0 | 0.0 (0.0-9.3) | 0 | 0.0 (0.0-19.8) | 0 | 0.0 (0.0-2.3) |
| 10-19 | 0 | 0.0 (0.0-95.4) | 1 | 2.9 (0.4-20.7) | 0 | 0.0 (0.0-12.8) | 5 | 2.6 (1.1-6.3)c | |
| 20-29 | 0 | 0.0 (0.0-887.9) | 0 | 0.0 (0.0-116.5) | 0 | 0.0 (0.0-137.7) | 2 | 11.3 (2.8-45.1)c | |
| p trend | - | 0.40 | - | 0.002 | |||||
| Leukaemia | 0-9 | 18 | 55.7 (35.1-88.4)e | 3 | 8.8 (2.9-27.4)c | 2 | 0.9 (0.2-3.5) | 1 | 0.6 (0.0-3.4) |
| 10-19 | 5 | 29.9 (12.5-71.9)e | 1 | 6.2 (0.2-34.3) | 2 | 1.5 (0.4-6.1) | 2 | 2.1 (0.5-8.4) | |
| 20-29 | 0 | 0.0 (0.0-239.3) | 0 | 0.0 (0.0-186.3) | 0 | 0.0 (0.0-37.7) | 0 | 0.0 (0.0-36.5) | |
| p trend | 0.10 | 0.63 | 0.74 | 0.47 | |||||
SMR = Standardised mortality ratio; SIR = Standardised incidence ratio; CI = Confidence interval
Using Swiss rates as expecteds for Germany, and Belgian rates as expecteds for both France and the Netherlands, for cancer sites for which sufficient detail was not available from home-country national rates.
Excluding France, Germany and Italy.
p<0.05
p<0.01
p<0.001
SMR = Standardised mortality ratio; SIR = Standardised incidence ratio; CI = Confidence interval
Using Swiss rates as expecteds for Germany, and Belgian rates as expecteds for both France and the Netherlands, for cancer sites for which sufficient detail was not available from home-country national rates.
Excluding France, Germany and Italy
p<0.05
p<0.01
p<0.001